Advertisement

Flow Cytometry as Platform for Biomarker Discovery and Clinical Validation

  • Olga Millán
  • Mercè BrunetEmail author
Reference work entry
Part of the Biomarkers in Disease: Methods, Discoveries and Applications book series

Abstract

Flow cytometry (FC) is a highly versatile method that is constantly expanding. Its field of application is extremely wide (oncology, hematology, transplantation, autoimmunity, tumor immunology, chemotherapy, etc.), making it highly useful not only in the discovery of new biomarkers but also in clinical validation and routine implementation. FC simultaneously provides information about the phenotypic and functional characteristics of cells and enables quantification of large numbers of cells and assessment of their subset distribution, activation status, cytokine production profile, and other cellular functions. Furthermore, because FC allows the performance of many different types of assays (immunophenotyping, intracellular staining, cell cycle, cell proliferation, apoptosis, phosphoflow assays, etc.), it yields different types of information, ranging from elucidation of mechanisms of action (for drugs and disease progression) to functional assays. This technique plays an important role in the prioritization, verification, and clinical validation of new biomarkers. However, because of the high complexity of the panels of reagents involved, greater expertise is needed for correct interpretation of the data obtained, and the technique continues to have several limitations. One of the most important limitations is the lack of standardization in assay and instrument setup, as well as the absence of good quality controls, especially external controls. There is a need to develop mathematical algorithms able to predict clinical evolution/disease progression based on FC measurement of biomarkers. New biostatistics models should be developed to establish the most appropriate correlation among biomarkers, drug effect, and clinical outcome, which would allow personalized treatment.

Keywords

Flow cytometry Biomarkers Standardization Validation Clinical evolution Drug response 

List of Abbreviations

AR

Acute Rejection

BrDU

Bromodeoxyuridine

C&T

Cytometric Setup and Tracking

cGVHD

Chronic Graft-Versus-Host Disease

CSC

Cancer Stem Cell

DNA

Deoxyribonucleic Acid

EDTA

Ethylenediaminetetraacetic Acid

FC

Flow Cytometry

ICS

Intracellular Staining

IFN-γ

Interferon-γ

IL

Interleukin

PBMC

Peripheral Blood Mononuclear Cells

S6RP

S6 Ribosomal Protein

SLE

Systemic Lupus Erythematosus

SOPs

Standard Operating Procedures

TCR

T-Cell Receptor

Treg

Regulatory T Cells

References

  1. Akoglu B, Kriener S, Martens S, et al. Faust, Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients. Clin Exp Med. 2009;9(4):259–62.PubMedCrossRefGoogle Scholar
  2. Álvarez-Barrientos A, Arroyo J, Canton R, et al. Applications of flow cytometry to clinical microbiology. Clin Microbiol Rev. 2000;13:167–95.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Bandura DR, Baranov VI, Ornatsky OI, et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem. 2009;81(16):6813–22.PubMedCrossRefGoogle Scholar
  4. Benítez F, Najafian N. Novel noninvasive assays to predict transplantation rejection and tolerance: enumeration of cytokine-producing alloreactive T cells. Clin Lab Med. 2008;28:365–73.PubMedCrossRefGoogle Scholar
  5. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol. 2008;19(7):1419–29.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation. 2004;77:1815–20.PubMedCrossRefGoogle Scholar
  7. Brown M, Wittwer C. Flow cytometry: principles and clinical applications in hematology. Clin Chem. 2000;46:1221–9.PubMedGoogle Scholar
  8. Burkhard G, Reinhard K, Spaniol K, et al. Flow cytometry in cancer stem cell analysis and separation. Cytometry A. 2012;81A(4):284–93.CrossRefGoogle Scholar
  9. Carey JL, McCoy JP, Keren DF. Chapter 14. Flow cytometry in clinical diagnosis. 4th ed. Weikersheimer J; 2007, American Society for Clinical Pathology Press (ASCP), Chicago IL, p. 275–294.Google Scholar
  10. Comin-Anduix B, Sazegar H, Chodon T, et al. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010;5(9):2711.CrossRefGoogle Scholar
  11. De Luca A, Rindi L, Celi A, et al. Intracellular detection of interleukin 17 and other cytokines in human bronchoalveolar lavage fluid: a first assessment. Immunol Lett. 2012;141(2):204–9.PubMedCrossRefGoogle Scholar
  12. Dieterlen MT, Bittner HB, Klein S, et al. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood. Cytometry B Clin Cytom. 2012;82(3):151–7.PubMedCrossRefGoogle Scholar
  13. Drevs J, Medinger M, Schmidt-Gersbach C, et al. Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr Drug Targets. 2003;4(2):113–21.PubMedCrossRefGoogle Scholar
  14. Givan AL. Flow cytometry: first principles. 2nd ed. New York: Wiley; 1992.Google Scholar
  15. Hengel RL, Nicholson JKA. An update on the use of flow cytometry in HIV infection and AIDS. Clin Lab Med. 2001;21:841–56.PubMedGoogle Scholar
  16. Herzenberg LA, Tung J, Moore WA, et al. Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol. 2006;7(7):681–5.PubMedCrossRefGoogle Scholar
  17. Horsburgh T, Martin S, Robson AJ. The application of flow cytometry to histocompatibility testing. Transpl Immunol. 2000;8:3–15.PubMedCrossRefGoogle Scholar
  18. Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986–2010.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Kim SH, Oh EJ, Kim MJ, et al. Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant Proc. 2007;39(10):3057–60.PubMedCrossRefGoogle Scholar
  20. Kirmizis D, Chatzidimitriou D, Chatzopoulou F, et al. Applications of flow cytometry in solid organ allogeneic transplantation. In: Schmid I, editor. Clinical flow cytometry – emerging 2012 applications. InTech. 2012, ISBN: 978-953-51-0575-6, Croatia, Available from: http://www.intechopen.com/books/clinical-flow-cytometry-emerging-applications/applications-of-flow-cytometryin-solid-organ-allogeneic-transplantation
  21. Kumar P, Satchidanandam V. Ethyleneglycol-bis-(beta-aminoethylether) tetraacetate as a blood anticoagulant: preservation of antigen-presenting cell function and antigen-specific proliferative response of peripheral blood mononuclear cells from stored blood. Clin Diagn Lab Immunol. 2000;7(4):578–83.PubMedPubMedCentralGoogle Scholar
  22. Kuzmina Z, Krenn K, Petkov V, et al. CD19 (+) CD21 (low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood. 2013;121(10):1886–95.PubMedCrossRefGoogle Scholar
  23. Lepin EJ, Zhang Q, Zhang X, et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant. 2006;6(7):1560–71.PubMedCrossRefGoogle Scholar
  24. Maecker HT, Rinfret A, D’Souza P, et al. Standardization of cytokine flow cytometry assays. BMC Immunol. 2005;6:13.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Maecker HT, McCoy JP, FOCIS Human Immunophenotyping Consortium, et al. A model for harmonizing flow cytometry in clinical trials. Nat Immunol. 2010;11(11):975–8.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12(3):191–200.PubMedPubMedCentralGoogle Scholar
  27. Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant. 2007;7(2):309–19.PubMedCrossRefGoogle Scholar
  28. McKinnon LR, Nyanga B, Chege D, et al. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol. 2011;187(11):6032–42.PubMedCrossRefGoogle Scholar
  29. Millán O, Benítez C, Guillén D, et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol. 2010;137(3):337–46.PubMedCrossRefGoogle Scholar
  30. Millán O, Rafael-Valdivia L, Torrademe E, et al. Intracellular IFN-gamma and Il-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. Cytokine. 2013;61(2):556–64.PubMedCrossRefGoogle Scholar
  31. Nickel P, Presber F, Bold G, Biti D, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells indentifies T-cell presensitization and correlates with graft function al 6 and 12 months in renal-transplant recipients. Transplantation. 2004;78(11):1640–6.PubMedCrossRefGoogle Scholar
  32. Nomura LE, Emu B, Hoh R, et al. IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. AIDS Res Ther. 2006;3:18.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol. 2001;3(3):67–70.PubMedGoogle Scholar
  34. Ornatsky O, Bandura D, Baranov V, et al. Highly multiparametric analysis by mass cytometry. J Immunol Methods. 2010;361(1–2):1–20.PubMedCrossRefGoogle Scholar
  35. Pallier A, Hillion S, Danger R, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int. 2010;78(5):503–13.PubMedCrossRefGoogle Scholar
  36. Relja B, Meder F, Wilhelm K, et al. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010;26(5):735–41.PubMedCrossRefGoogle Scholar
  37. San Segundo D, Fernández-Fresnedo G, Ruiz JC, et al. Two-year follow-up of a prospective study of circulating regulatory T cells in renal transplant patients. Clin Transplant. 2010;24(3):386–93.PubMedCrossRefGoogle Scholar
  38. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211–25.PubMedCrossRefGoogle Scholar
  39. Shapiro HM. Practical flow cytometry. 4th ed. New York: Wiley; 2003.CrossRefGoogle Scholar
  40. Subasic D, Karamehic J, Delic-Sarac M, et al. Monitoring of disease biomarkers activity and immunophenotyping as important factors in SLE clinical management. Med Arh. 2012;66(5):336–9.CrossRefGoogle Scholar
  41. Tuaillon E, Al Tabaa Y, Baillat V, et al. Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count. Cytometry B Clin Cytom. 2009;76(4):249–60.PubMedCrossRefGoogle Scholar
  42. Van Roon JA, Hartgring SA, Wenting-van Wijk M, et al. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):664–9.PubMedCrossRefGoogle Scholar
  43. Walter GJ, Evans HG, Menon B, et al. Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4 + CD45ro + CD25 + CD127 (low) regulatory T cells. Arthritis Rheum. 2013;65(3):627–38.PubMedPubMedCentralCrossRefGoogle Scholar
  44. White CA, Weaver RL, Grillo-López AJ. Antibody-targeted immunotherapy for treatment of malignancy. Ann Rev Med. 2001;52:125–45.PubMedCrossRefGoogle Scholar
  45. Wu DY, Patti-Diaz L, Hill CG. Development and validation of flow cytometry methods for pharmacodynamic clinical biomarkers. Bioanalysis. 2010;2(9):1617–26.PubMedCrossRefGoogle Scholar
  46. Xu Y, Jin J, Wang H, et al. The regulatory/cytotoxic infiltrating T cells in early renal surveillance biopsies predicts acute rejection and survival. Neprol Dial TX. 2012;27:2958–65.CrossRefGoogle Scholar
  47. Younes SA, Yassine-Diab B, Dumont AR, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med. 2003;198(12):1909–22.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Pharmacology and Toxicology Laboratory, Centro de Diagnóstico Biomédico, CIBERehd, IDIBAPS, Hospital Clínico de BarcelonaBarcelona UniversityBarcelonaSpain

Personalised recommendations